Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › neostigmine

neostigmine

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of neostigmine

31 trials tracked of neostigmine: 28 in phase 3 or 4 and 13 with published results. The most-cited published study has 374 citations.

31Trials tracked
28Phase 3 & 4
0Recruiting
13With published results
Phase distribution
Phase 4 19 Phase 3 9 Phase 1 1 Other / NA 2
  1. Phase 3 Comparison of Sugammadex (MK-8616/Org 25969) With Neostigmine Administered at 1-2 Post-tetanic Counts (PTCs) After Administration of Rocuronium or Vecuronium (19.4.302/P05945/MK-8616-025) Completed · 374 cited
  2. Phase 3 Comparison of Sugammadex (Org 25969) With Neostigmine as Reversal Agents for Rocuronium or Vecuronium at Reappearance of T2 (P05960) Completed · 237 cited
  3. Phase 4 The Effect of Sugammadex Versus Neostigmine on Postoperative Pulmonary Complications Completed · 148 cited
  4. Phase 4 Neuromuscular Blockade on Shoulder Pain of Elderly Completed · 28 cited
  5. Phase 4 Deep Neuromuscular Block for Laparoscopic Surgery Completed · 23 cited
  6. Phase 4 Quality of Recovery After Reversal With Neostigmine or Sugammadex. Completed · 18 cited
Show 25 more trials
  1. Phase 4 Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery Completed · 17 cited
  2. Phase 4 Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular Completed · 12 cited
  3. Phase 3 Recovery of Diaphragmatic Function After Neuromuscular Blockade and Sugammadex Completed · 9 cited
  4. Phase 4 Sugammadex To IMprove Bowel Function Completed · 3 cited
  5. Phase 4 Role of Sugammadex as Reversal Agent in Patients Extubated Immediately After Isolated Coronary Artery Bypass Grafting Surgery Completed
  6. Phase 4 Postoperative Urinary Retention After Reversal of Neuromuscular Block by Neostigmine Versus Sugammadex Completed
  7. Phase 4 Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade at the End of Kidney Transplantation Surgery Completed
  8. Phase 4 Effect of Neuromuscular Reversal With Sugammadex on Postoperative Recovery Profile Completed
  9. Phase 4 Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency Completed
  10. Phase 4 Investigation of Sugammadex in Outpatient Urological Procedures Completed
  11. Phase 4 Effect of Neuromuscular Blockade and Reversal on Breathing Completed
  12. Phase 4 Optimizing Post-operative Recovery in Bariatric Patients With Obstructive Sleep Apnea Undergoing Outpatient Surgery: A Comparison of Sugammadex and Neostigmine Completed
  13. Phase 4 Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications Completed
  14. Phase 4 Use of Sugammadex for Reversal of Paralysis in Microlaryngoscopy Completed
  15. Phase 4 Impact of Anesthetic Choice (Sevoflurane Versus Desflurane) on Airway Reflex Recovery in the Context of Antagonized Neuromuscular Block Completed
  16. Phase 4 Efficacy and Safety of Standard Oral Colonoscopic Preparations With or Without Neostigmine Compared to Pulse-Irrigation Colonic Lavage Completed
  17. Phase 3 Comparision of Different Dose of Neostigmine at Advanced Decurarization Completed
  18. Phase 3 Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981) Completed
  19. Phase 3 Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced Neuromuscular Blockade in Adults Undergoing Elective Open Abdominal Procedure (19.4.334) (P05774) Completed
  20. Phase 3 Comparison of Sugammadex With Neostigmine as Reversal Agents for Rocuronium at Reappearance of T2 (Study P06101) Completed
  21. Phase 3 Comparison of 2.0 mg/kg Sugammadex and Neostigmine at Reappearance of T2 in Chinese and European Subjects (Study 19.4.324)(P05768AM1)(COMPLETED) Completed
  22. Phase 3 Comparison of Sugammadex With Neostigmine During Laparoscopic Cholecystectomy or Appendectomy (P05699) Completed
  23. Phase 1 Epidural Neostigmine for Labor Pain Completed
  24. N/A Use of Neuromuscular Blocking Agents and Neuromuscular Monitoring in 7 Danish Teaching Hospitals Completed
  25. N/A The Impacts of Surgical Visibility Through Deep Neuromuscular Blockade on Intraocular Pressure in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy Completed

Showing the 31 most-cited and recently-updated of 31 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients
Diabetes & Endocrinology RCT
Sugammadex improves diaphragmatic excursion and reduces pulmonary complications in morbidly obese patients Sugammadex Helps Obese Patients Breathe Easier
A randomized double-blind controlled trial in 104 morbidly obese patients compared sugammadex (2 mg/kg) with neostigmine+atropine.
This new research shows that a specific reversal drug helps morbidly obese patients breathe better and avoid lung issues after surgery.
Apr 14, 2026
Neostigmine infusion in septic shock linked to lower TNF-alpha and 28-day mortality in single-center RCT
Emergency Medicine RCT
Neostigmine infusion in septic shock linked to lower TNF-alpha and 28-day mortality in single-center RCT Neostigmine infusion linked to lower inflammation and mortality in septic shock trial
A single-center randomized controlled trial in adult ICU patients with septic shock compared a 5-day neostigmine infusion (0.2 mg/hr) to pla…
Septic shock patients receiving neostigmine showed lower inflammation, better organ scores, and fewer deaths compared to those on placebo in…
Apr 7, 2026